13 hrs ago
Antibody halts cancer-related wasting condition: Study pinpoints a molecular cause of cachexia
New research raises the prospect of more effective treatments for cachexia, a profound wasting of fat and muscle occurring in about half of all cancer patients, raising their risk of death, according to scientists from Dana-Farber Cancer Institute.
Trending on the Topix Network
Fri Jul 11, 2014
Voice of America
Scientists Identify Cause of Cancer Wasting
Many become so frail, they cannot safely undergo potentially life-saving treatments./p pNow researchers have discovered a molecule that appears to be responsible for this condition, known as cachexia.
Thu Jul 10, 2014
GlycoMimetics Appoints Mark A. Goldberg, M.D. to Board of Directors
GAITHERSBURG, Md. -- -- GlycoMimetics, Inc. announced today the addition of Mark A. Goldberg, M.D. to its Board of Directors.
Lakeville's Bob Friedman hits the quarter million mark in Pan-Mass Challenge donations
The Lakeville resident, who practiced medicine in Middleboro for 34 years before entering semi-retirement, has raised $250,000 since 2000 for the Dana Farber Cancer Institute.
Wed Jul 09, 2014
Scientists publish a deep look at DNA mutations in lung cancer
The largest and most comprehensive genomic study of the most common kind of lung cancer has revealed an exhaustive library of mutations carried by tumors, providing information that could help guide scientists' efforts to devise new treatments.
York residents will ride in Pan-Mass Challenge
Four residents from York will participate in the 35th annual Pan-Mass Challenge on August 2-3, the largest single athletic fundraising event in the country.
Wed Jul 02, 2014
The Washington Post
Dimon's Cancer Has 90% Cure Rate With Demanding Therapy: Health
The type of cancer Jamie Dimon has is curable in as many as 90 percent of cases with a treatment regimen that poses challenges for his demanding work schedule as chairman and chief executive officer of JPMorgan Chase & Co.
Thu Jun 26, 2014
J&J Enters Cancer Research Partnership With Dana-Farber Cancer Institute
Johnson & Johnson Innovation and Janssen Biotech recently announced a three year immuno-oncology lung cancer collaboration with the Dana-Faber Cancer Institute's Belfer Institute for Applied Cancer Science.
Tue Jun 24, 2014
Johnson & Johnson Innovation Center to fund $10 million Janssen Biotech, Dana-Farber partnership
A week after announcing partnerships with six Massachusetts-based companies, Johnson & Johnson Innovation Center said it will fund a $10 million partnership with Janssen Biotech, Inc. and Dana-Farber Cancer Institute to do work on lung cancer immunotherapy drugs.
Thu Jun 19, 2014
Scientists identify additional challenges in KRAS-driven cancers
Cancers driven by - and dependent on - the potent mutated cancer gene KRAS have an especially poor prognosis, and three decades of scientific attempts have failed to produce drugs that can attack KRAS and halt the tumors' runaway growth.
Mon Jun 16, 2014
Cellceutix Clinical Trial Of Anti-Cancer Drug Kevetrin Entering Eighth Cohort
Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that the safety committee overseeing the Phase 1 clinical trial evaluating Cellceutix's lead anti-cancer drug Kevetrin for solid tumors being conducted at Dana-Farber Cancer ... (more)
Trovagene enters into clinical collaboration with Dana-Farber Cancer Institute
Trovagene, Inc. today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.